Mark S. Sulkowski, MD; Joseph J. Eron, MD; David Wyles, MD; et al.
This randomized trial reports high rates of sustained virologic response in the first part of a open-label study of ombitasvir, paritaprevir (co-dosed with ritonavir), and dasabuvir with ribavirin for 63 patients with hepatitis C virus genotype 1 and human immunodeficiency virus 1 co-infection.